Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$472.35 USD

472.35
432,975

+3.17 (0.68%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 249)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Amedisys or Chemed: Which is a Better Investment Choice?

After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).

    Why Should Investors Add Amedisys (AMED) to Their Portfolio?

    Amedisys (AMED) rides high on solid prospects with new opportunities within home health and hospice services segments.

      Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

      IDEXX Laboratories (IDXX) continues to boost investor's confidence with strong companion animal business along with balanced growth across all segments.

        Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?

        Several recent FDA product-approvals boost investors' trust in Edwards Lifesciences' (EW) stock.

          Here's Why You Should Add Chemed (CHE) to Your Portfolio

          Chemed (CHE) bolsters investor's confidence with continued strength in Roto-Rooter business.

            Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now

            BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.

              BD (BDX) Inks New Deal to Strengthen Foothold in STI Space

              BD (BDX) is a leading player in providing solutions for women's health and sexually transmitted infections. Its latest development is likely to lend the company a competitive edge in the niche space.

                Boston Scientific MultiSENSE Study on HeartLogic Positive

                Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.

                  Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care

                  Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.

                    Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1

                    Neogen (NEOG) rides high on balanced growth across all business segments.

                      Halyard Health (HYH) Announces Positive Data on COOLIEF

                      Halyard Health's (HYH) positive clinical data on COOLIEF will boost fortunes in the chronic pain space.

                        TransEntrix Progresses Toward FDA Approval for Senhance

                        TransEnterix's (TRXC) gradual progress toward FDA's approval for Senhance Surgical Robotic System will boost its presence in the lucrative U.S. market.

                          Surmodics Receives FDA's Approval for PTA Balloon Catheter

                          Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.

                            Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5

                            Varian Medical (VAR) is consistently trying to turn around its Oncology Systems business.

                              Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?

                              Cardiovascular (CSII) expects Q1 revenues to be affected by the Harvey and Irma hurricanes. However, the long-term growth prospects are unlikely to be affected.

                                Bruker (BRKR) Strong on Product Launches Amid Currency Woes

                                Bruker (BRKR) continues to see solid contributions from NMR and Nano businesses. Also, a raised guidance is indicative of brighter prospects.

                                  Masimo (MASI) Launches Rad-97 CO-Oximeter Post FDA Clearance

                                  Masimo's (MASI) newly-launched Rad-97 Pulse CO-Oximeter will strengthen the company's presence in the Advanced Monitoring Technologies space.

                                    5 MedTech Stocks to Pick for Stellar Returns

                                    While the MedTech industry has been grappling with multiple issues, these stocks with high growth potential can be great bets.

                                      McKesson to Gain From Distribution Business Amid Pricing Woes

                                      McKesson Corporation's (MCK) Distribution business driven by market growth and acquisitions is expected to aid growth. However, pricing remains a concern.

                                        Varian Conducts Clinical Workshop, Strengthens Algeria Hold

                                        Varian (VAR) has 30 systems operating in Algeria at the moment. The latest development signifies the company's long-term goal of serving six million cancer patients every year.

                                          AngioDynamics' BioFlo Platform Strong, Debt Levels High

                                          AngioDynamics' (ANGO) exclusive Endexo technology in the BioFlo unit is expected to enhance the company's growth trajectory. However, high debt levels limit the company's core business strategies.

                                            Phibro Animal Health Expands Globally Amid Tough Competition

                                            Phibro (PAHC) is consistently trying to expand globally to counter the tough competition in the animal health and mineral nutrition space.

                                              Allscripts' Latest Initiative Eradicates Price Ambiguity

                                              Lately, Allscripts' (MDRX) management has been focusing on various restructuring initiatives, research and development plans and launch of exclusive products.

                                                Thermo Fisher Fundamentals Impressive Amid Tough Competition

                                                Thermo Fisher (TMO) continues to gain considerable synergies from FEI acquisition. A raised guidance buoys optimism.

                                                  Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet

                                                  Surmodics' (SRDX) promising data on SurVeil DCB will boost its fortunes in the symptomatic peripheral artery disease space.